Drug Trial Radar · NCT03401112
A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)
Last checked: Nov 20, 2026Latest source record: May 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Jan 26, 2018
Primary completion
Aug 28, 2020
Study completion Aug 28, 2020
Sponsor
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Imara, Inc.
- First posted
- Jan 17, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study of IMR-687 in adult participants with sickle cell anemia (SCA) (homozygous HbSS or sickle-β0 thalassemia).
Conditions
- Sickle Cell Disease
Interventions
IMR-687Drug
Oral administration of IMR-687 once daily with or without HU.
PlaceboDrug
Oral administration of placebo once daily with or without HU.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number Of Participants With Treatment-emergent Adverse Events (TEAEs) And Serious Adverse Events (SAEs)Time frame: Day 1 (after dosing) through up to Week 24
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
UCSF Benioff Children's Hospital Oakland
Oakland, California
University of Connecticut Health Center
Farmington, Connecticut
Foundation for Sickle Cell Disease Research
Hollywood, Florida
University of Illinois
Chicago, Illinois
Loretto Hospital
Chicago, Illinois
Medical University of South Carolina
Charleston, South Carolina
Baylor Scott & White Health
Temple, Texas
Sandwell & West Birmingham Hospital
Birmingham, United Kingdom
Bristol Haematology and Oncology Centre
Bristol, United Kingdom
Royal London Hospital
London, United Kingdom
University College London Hospital
London, United Kingdom
Guy's Hospital
London, United Kingdom
Oxford Cancer & Haematology Centre, The Churchill Hospital
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.